The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study
Abstract Objective Pancreatectomy remains associated with a high incidence of complications. In certain cases, patients with pancreatic ductal adenocarcinoma (PDAC) face challenges in removing intraperitoneal drainage after surgery, leading to potential delays in the administration of adjuvant chemo...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14262-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849325911196827648 |
|---|---|
| author | Dong Xu Nan Lv Qianqian Wang Yang Wu Kai Zhang Yi Miao Jishu Wei Min Tu Kuirong Jiang |
| author_facet | Dong Xu Nan Lv Qianqian Wang Yang Wu Kai Zhang Yi Miao Jishu Wei Min Tu Kuirong Jiang |
| author_sort | Dong Xu |
| collection | DOAJ |
| description | Abstract Objective Pancreatectomy remains associated with a high incidence of complications. In certain cases, patients with pancreatic ductal adenocarcinoma (PDAC) face challenges in removing intraperitoneal drainage after surgery, leading to potential delays in the administration of adjuvant chemotherapy (AC) and potentially impacting survival outcomes. The objective of this study was to evaluate the feasibility and potential benefits of AC in PDAC patients who are unable to remove intraperitoneal drainage over 30 days. Methods Between January 2021 and December 2022, a total of 220 patients with resected PDAC received AC at our center. Among them, 84 patients experienced persistent intraperitoneal drainage lasting more than 30 days postoperatively. Of these, 38 patients (45.2%) initiated AC despite the ongoing presence of drainage and were classified as the AC(d+) group, while the remaining 46 patients (54.8%) began AC only after successful drainage removal, and were categorized as the AC(d−) group. The other 136 patients, who underwent prompt removal of intraperitoneal drainage, were assigned to the AC(pr) group. Baseline information, surgery-related outcomes, and chemotherapy-related adverse events were collected and compared between the two groups, and factors that affected recurrence-free survival (RFS) were also analysed. Results Of the 220 patients included in the study, 107 (48.7%) experienced grade 3–4 chemotherapy-related adverse events. The interval from surgery to the initiation of AC was similar between the AC(d+) and AC(pr) groups (50 vs. 57 days, P = 0.108). However, it was significantly shorter in the AC(d+) group compared to the AC(d−) group (50 vs. 61 days, P = 0.015). Notably, no additional chemotherapy-related adverse events were observed in the AC(d+) group compared to either the AC(d−) or AC(pr) groups. The estimated 1-year and 2-year survival rates were 85.6% and 60.5%, respectively, for the AC(d−) group, and 95.8% and 61.0% for the AC(d+) group. In the AC(pr) group, the corresponding survival rates were 89.1% and 64.0%. Cox multivariate regression analysis demonstrated that tumour grade differentiation, completed six cycles of therapy, the interval from surgery to the initiation of AC and resection margins were independent factors affecting RFS. Conclusion Administering AC was safe for patients who underwent resection for PDAC and encountered challenges in the prompt removal of intraperitoneal drainage beyond 30 days post-surgery. The proactive management of preventing delays in chemotherapy administration could reduce the early recurrence risk in this particular patient cohort. |
| format | Article |
| id | doaj-art-79dc79dbd7e549cdb97ee61d30796c79 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-79dc79dbd7e549cdb97ee61d30796c792025-08-20T03:48:18ZengBMCBMC Cancer1471-24072025-05-012511910.1186/s12885-025-14262-1The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort studyDong Xu0Nan Lv1Qianqian Wang2Yang Wu3Kai Zhang4Yi Miao5Jishu Wei6Min Tu7Kuirong Jiang8Pancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityPancreas Center, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), Pancreas Research Institute, Nanjing Medical UniversityAbstract Objective Pancreatectomy remains associated with a high incidence of complications. In certain cases, patients with pancreatic ductal adenocarcinoma (PDAC) face challenges in removing intraperitoneal drainage after surgery, leading to potential delays in the administration of adjuvant chemotherapy (AC) and potentially impacting survival outcomes. The objective of this study was to evaluate the feasibility and potential benefits of AC in PDAC patients who are unable to remove intraperitoneal drainage over 30 days. Methods Between January 2021 and December 2022, a total of 220 patients with resected PDAC received AC at our center. Among them, 84 patients experienced persistent intraperitoneal drainage lasting more than 30 days postoperatively. Of these, 38 patients (45.2%) initiated AC despite the ongoing presence of drainage and were classified as the AC(d+) group, while the remaining 46 patients (54.8%) began AC only after successful drainage removal, and were categorized as the AC(d−) group. The other 136 patients, who underwent prompt removal of intraperitoneal drainage, were assigned to the AC(pr) group. Baseline information, surgery-related outcomes, and chemotherapy-related adverse events were collected and compared between the two groups, and factors that affected recurrence-free survival (RFS) were also analysed. Results Of the 220 patients included in the study, 107 (48.7%) experienced grade 3–4 chemotherapy-related adverse events. The interval from surgery to the initiation of AC was similar between the AC(d+) and AC(pr) groups (50 vs. 57 days, P = 0.108). However, it was significantly shorter in the AC(d+) group compared to the AC(d−) group (50 vs. 61 days, P = 0.015). Notably, no additional chemotherapy-related adverse events were observed in the AC(d+) group compared to either the AC(d−) or AC(pr) groups. The estimated 1-year and 2-year survival rates were 85.6% and 60.5%, respectively, for the AC(d−) group, and 95.8% and 61.0% for the AC(d+) group. In the AC(pr) group, the corresponding survival rates were 89.1% and 64.0%. Cox multivariate regression analysis demonstrated that tumour grade differentiation, completed six cycles of therapy, the interval from surgery to the initiation of AC and resection margins were independent factors affecting RFS. Conclusion Administering AC was safe for patients who underwent resection for PDAC and encountered challenges in the prompt removal of intraperitoneal drainage beyond 30 days post-surgery. The proactive management of preventing delays in chemotherapy administration could reduce the early recurrence risk in this particular patient cohort.https://doi.org/10.1186/s12885-025-14262-1Pancreatic cancerPostoperative pancreatic fistulaIntraperitoneal drainageAdjuvant chemotherapyRecurrence-free survival |
| spellingShingle | Dong Xu Nan Lv Qianqian Wang Yang Wu Kai Zhang Yi Miao Jishu Wei Min Tu Kuirong Jiang The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study BMC Cancer Pancreatic cancer Postoperative pancreatic fistula Intraperitoneal drainage Adjuvant chemotherapy Recurrence-free survival |
| title | The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study |
| title_full | The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study |
| title_fullStr | The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study |
| title_full_unstemmed | The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study |
| title_short | The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post-surgery: a retrospective cohort study |
| title_sort | feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal drainage post surgery a retrospective cohort study |
| topic | Pancreatic cancer Postoperative pancreatic fistula Intraperitoneal drainage Adjuvant chemotherapy Recurrence-free survival |
| url | https://doi.org/10.1186/s12885-025-14262-1 |
| work_keys_str_mv | AT dongxu thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT nanlv thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT qianqianwang thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT yangwu thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT kaizhang thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT yimiao thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT jishuwei thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT mintu thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT kuirongjiang thefeasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT dongxu feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT nanlv feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT qianqianwang feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT yangwu feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT kaizhang feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT yimiao feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT jishuwei feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT mintu feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy AT kuirongjiang feasibilityandpotentialbenefitsofadministeringadjuvantchemotherapyinresectedpancreaticcancerpatientsunabletopromptlyremoveintraperitonealdrainagepostsurgeryaretrospectivecohortstudy |